Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan Nv Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,961,844
  • Shares Outstanding, K 514,780
  • Annual Sales, $ 11,908 M
  • Annual Income, $ 696,000 K
  • 36-Month Beta 1.34
  • Price/Sales 1.76
  • Price/Cash Flow 5.15
  • Price/Book 1.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.58 +5.52%
on 03/26/18
41.94 -2.93%
on 04/10/18
+1.84 (+4.73%)
since 03/23/18
3-Month
38.10 +6.85%
on 02/09/18
47.17 -13.70%
on 01/24/18
-6.14 (-13.11%)
since 01/23/18
52-Week
29.39 +38.52%
on 08/15/17
47.82 -14.87%
on 01/23/18
+3.88 (+10.53%)
since 04/21/17

Most Recent Stories

More News
Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program will be presented at the American Academy of Neurology...

MYL : 40.70 (-0.05%)
Wired News - Mylan to Collaborate with Fujifilm Kyowa Kirin Biologics for Commercializing Biosimilar to Humira(R) (adalimumab)

Stock Monitor: SteadyMed Post Earnings Reporting

MYL : 40.70 (-0.05%)
Generic Drugs Stocks' Research Reports Released on Mylan, Momenta Pharma, Rigel Pharma, and SCYNEXIS

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on MYL, MNTA, RIGL, and SCYX which can be accessed for free by signing up to www.wallstequities.com/registration....

MYL : 40.70 (-0.05%)
SCYX : 1.28 (-3.03%)
MNTA : 20.05 (-1.72%)
RIGL : 3.60 (-6.25%)
Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar

Mylan (MYL) is partnering with Fujifilm Kyowa to commercialize a biosimilar to Humira (adalimumab).

MYL : 40.70 (-0.05%)
ABBV : 93.19 (+0.64%)
AMGN : 174.89 (+1.94%)
BIIB : 262.69 (-0.13%)
Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug

Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.

MYL : 40.70 (-0.05%)
MNTA : 20.05 (-1.72%)
TEVA : 17.96 (+0.79%)
RHHBY : 27.8800 (+0.52%)
Investor Day Highlights Durability of Mylan's Global Platform

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today will host an Investor Day, which focuses on the global powerhouse's differentiation and durability, including its longtime mission to expand...

MYL : 40.70 (-0.05%)
Mylan to Leverage its World-Class Scientific Platform to Develop a Novel Delivery for Meloxicam, a Non-Opioid Pain Medication

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has acquired global development and marketing rights from Prayog Labs LLC to bring to market a fast-acting Meloxicam as a...

MYL : 40.70 (-0.05%)
Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira(R) (adalimumab)

Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced the company will partner with Mylan N.V. (NASDAQ:MYL) to commercialize FKB327, a biosimilar to Humira(R) (adalimumab) developed by...

MYL : 40.70 (-0.05%)
Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab)

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced it is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to Humira® (adalimumab) developed by...

MYL : 40.70 (-0.05%)
Mylan Nv Rises 3.31% on Heavy Volume: Watch For Potential Pullback

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $40.40 to a high of $41.72. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of $40.99...

MYL : 40.70 (-0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Key Turning Points

2nd Resistance Point 41.27
1st Resistance Point 41.00
Last Price 40.70
1st Support Level 40.44
2nd Support Level 40.15

See More

52-Week High 47.82
Fibonacci 61.8% 40.78
Last Price 40.70
Fibonacci 50% 38.60
Fibonacci 38.2% 36.43
52-Week Low 29.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar